Epidemiological Characteristics of Cases of COVID-19 Reinfection in Rivers State, Nigeria
Owhonda Golden, Des-Wosu Ihuoma, Onu Hastings, Rogers Kanee, Eric Aigbogun Jr., Nwadiuto Ifeoma
International Journal of TROPICAL DISEASE & Health · pp. 25–31 · Published 7 May 2022
10.9734/ijtdh/2022/v43i930613Abstract
Background: The immune system’s antibodies have been trained to deal with similar-looking pathogens through prior infection or vaccination. With the COVID-19 pandemic, the protection level of convalescents’ antibodies against reinfections remains unclear. However, immunological solid evidence of antibodies protection against severity exists. Antibody levels are said to serve as a realistic stand-in for immune protection. How long these convalescent antibodies last in the body are still subject to research. Some findings document three months to eight months after infection to SARS-CoV-2. This study aimed to investigate the cases of COVID-19 reinfection in individuals who had recovered from an initial COVID-19 infection. Methods: A case series of individuals with a second positive COVID-19 PCR test result in Rivers State between March 2020 to June 2021. Results: Five cases were retested positive for COVID-19 with a median age of 46 (36-49) years, four males and a female. Four of the cases were found to have comorbidities of diabetes, hypertension, and human immunodeficiency virus (HIV). The median interval between the two episodes was 96 (37-196) days. Except for one asymptomatic case in the second episode, the convalescent participants had symptoms of COVID-19 in both the first and second episodes. Conclusion: This study is illustrative of the possibility of COVID-19 reinfection. The longevity of circulating antibodies and the existence of other chronic disease conditions like HIV and diabetes in the individual may be related to this outcome. While further studies are recommended, full vaccination of all eligible persons, including COVID-19 convalescent persons with comorbidities is advised. Continued adherence to non-pharmaceutical interventions will enhance the chances of safety in the pandemic.
Cited by 0
No indexed citations yet.
Related research
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Assessment of Anxiety in Healthcare Providers Working in ICU during COVID-19 Pandemics — shares topic coverage
- Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
- Elevated Levels of Lactate Dehydrogenase Predicts Poor Outcomes for Patients with COVID-19: A Review — shares topic coverage
- Addressing the Challenges of Containing Covid-19 Spread in a Rural, Poor Area in India: A Case Study — shares topic coverage
Article metrics
Real usage data collected on this platform.
2
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.